Les tki de 3e génération dans le cancer pulmonaire non à petites cellules EGFR muté ayant acquis une résistance secondaire t790m

Solenn Brosseau; Marie Viala; Andréa Varga; David Planchard; Benjamin Besse; Jean Charles Soria

doi:10.1016/j.bulcan.2015.05.001

Les tki de 3e génération dans le cancer pulmonaire non à petites cellules EGFR muté ayant acquis une résistance secondaire t790m

Translated title of the contribution: 3Rd generation's tki in lung cancer non-small cell EGFR-mutated having acquired a secondary t790m resistance

Solenn Brosseau, Marie Viala, Andréa Varga, David Planchard, Benjamin Besse, Jean Charles Soria

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation. Till now, patients suffering from EGFR-mutated NSCLC with acquired resistance have conventional treatment options. Two new 3rd generations' TKI, AZD9291 and rociletinib, are currently being studied in phases 1-3 studies. Preliminary results show relevant therapeutic properties in patients with T790M mutated-EGFR NSCLC. This review aims to highlight these new molecules, their effectiveness and their clinical toxicities in the treatment of advanced stages of NSCLC expressing the T790M mutation.

Translated title of the contribution	3Rd generation's tki in lung cancer non-small cell EGFR-mutated having acquired a secondary t790m resistance
Original language	French
Pages (from-to)	749-757
Number of pages	9
Journal	Bulletin du Cancer
Volume	102
Issue number	9
DOIs	https://doi.org/10.1016/j.bulcan.2015.05.001
Publication status	Published - 11 Sept 2015

Access to Document

10.1016/j.bulcan.2015.05.001

Cite this

@article{58d49bb97b504321bfe8f7050fd65334,

title = "Les tki de 3e g{\'e}n{\'e}ration dans le cancer pulmonaire non {\`a} petites cellules EGFR mut{\'e} ayant acquis une r{\'e}sistance secondaire t790m",

abstract = "Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation. Till now, patients suffering from EGFR-mutated NSCLC with acquired resistance have conventional treatment options. Two new 3rd generations' TKI, AZD9291 and rociletinib, are currently being studied in phases 1-3 studies. Preliminary results show relevant therapeutic properties in patients with T790M mutated-EGFR NSCLC. This review aims to highlight these new molecules, their effectiveness and their clinical toxicities in the treatment of advanced stages of NSCLC expressing the T790M mutation.",

keywords = "AZD9291, EGFR mutation, Non-small cell lung cancer, Rociletinib, T790M mutation",

author = "Solenn Brosseau and Marie Viala and Andr{\'e}a Varga and David Planchard and Benjamin Besse and Soria, {Jean Charles}",

note = "Publisher Copyright: {\textcopyright} 2015 Publi{\'e} par Elsevier Masson SAS pour la Soci{\'e}t{\'e} Fran{\c c}aise du Cancer.",

year = "2015",

month = sep,

day = "11",

doi = "10.1016/j.bulcan.2015.05.001",

language = "Fran{\c c}ais",

volume = "102",

pages = "749--757",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "9",

}

TY - JOUR

T1 - Les tki de 3e génération dans le cancer pulmonaire non à petites cellules EGFR muté ayant acquis une résistance secondaire t790m

AU - Brosseau, Solenn

AU - Viala, Marie

AU - Varga, Andréa

AU - Planchard, David

AU - Besse, Benjamin

AU - Soria, Jean Charles

PY - 2015/9/11

Y1 - 2015/9/11

N2 - Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation. Till now, patients suffering from EGFR-mutated NSCLC with acquired resistance have conventional treatment options. Two new 3rd generations' TKI, AZD9291 and rociletinib, are currently being studied in phases 1-3 studies. Preliminary results show relevant therapeutic properties in patients with T790M mutated-EGFR NSCLC. This review aims to highlight these new molecules, their effectiveness and their clinical toxicities in the treatment of advanced stages of NSCLC expressing the T790M mutation.

AB - Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation. Till now, patients suffering from EGFR-mutated NSCLC with acquired resistance have conventional treatment options. Two new 3rd generations' TKI, AZD9291 and rociletinib, are currently being studied in phases 1-3 studies. Preliminary results show relevant therapeutic properties in patients with T790M mutated-EGFR NSCLC. This review aims to highlight these new molecules, their effectiveness and their clinical toxicities in the treatment of advanced stages of NSCLC expressing the T790M mutation.

KW - AZD9291

KW - EGFR mutation

KW - Non-small cell lung cancer

KW - Rociletinib

KW - T790M mutation

UR - http://www.scopus.com/inward/record.url?scp=84941248379&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2015.05.001

DO - 10.1016/j.bulcan.2015.05.001

M3 - Article 'review'

C2 - 26235419

AN - SCOPUS:84941248379

SN - 0007-4551

VL - 102

SP - 749

EP - 757

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 9

ER -

Les tki de 3e génération dans le cancer pulmonaire non à petites cellules EGFR muté ayant acquis une résistance secondaire t790m

Abstract

Access to Document

Other files and links

Cite this